[May 22, 2014]

Research and Markets: Global Neuropathic Pain Report 2014: Hind Healthcare's Lidoderm/Versatis - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/xzjl6g/lidodermversatis) has announced the addition of the "Lidoderm/Versatis (Neuropathic Pain) - Forecast and Market Analysis to 2022" report to their offering.

Lidoderm, the topical analgesic 5% lidocaine patch (medicated plaster), was invented by US pharmacist Harry Hind (Hind Healthcare) and was approved by the FDA in March 1999 for the treatment of PHN. Teikoku Seiyaku then assumed from Hind full responsibility for manufacture of the Lidoderm patch, while Endo Pharmaceuticals has the rights to market the patch in the US. The patch was launched by Endo in the U in September 1999 for the treatment of PHN. In Europe, the patch was co-developed by Teikoku and the German drug company, Grünenthal, and was launched in the EU in 2007 under the brand name Versatis.

Scope

• Overview of Neuropathic pain, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on Lidoderm including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for Lidoderm for the top six countries from 2012 to 2022.
• Sales information covered for the US, France, Germany, Italy, Spain and the UK.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

• Painful Diabetic Neuropathy
• Postherpetic Neuralgia
• Trigeminal Neuralgia
• Etiology
• Pathophysiology

4 Disease Management

• Diagnosis
• Treatment Overview and Guidelines

5 Competitive Assessment

6 Lidoderm/Versatis

• Overview
• Efficacy
• Safety
• SWOT Analysis
• Forecast

7 Appendix

For more information visit http://www.researchandmarkets.com/research/xzjl6g/lidodermversatis

[ Back To TMCnet.com's Homepage ]